Stroke-Associated Letal Outcome with Hympavzi: Michael Makris on Pfizer’s Announcement
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”Important.
Pfizer has just announced that a person with hemophilia, in their marstacimab (Hympavzi) clinical trial program, has died from a thrombotic stroke.
I attach the letter they sent to a number of patient organisations including the World Federation of Hemophilia.
The information provided in the letter is minimal.
I hope they reach out to all hemophilia doctors worldwide who can potentially prescribe this drug to inform them about this event, and the other thrombotic event in the same clinical trial that was previously disclosed at the EAHAD and ISTH meetings.
The patient who died, had hemophilia A with an inhibitor.
Marstacimab is at present only approved for persons with hemophilia A and B without an inhibitor.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage
-
Feb 23, 2026, 11:29Emma Lefrancais: Uncovering A Key Role for The IL-33/ST2 Axis in Platelet Biology with Lucie Gelon
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V JÖ‰ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem KhachatryanÖ‰ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?